相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
FUNDAMENTALS OF ANTIBODY-RELATED THERAPY AND DIAGNOSTICS
Huguette Albrecht et al.
DRUGS OF TODAY (2009)
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2008)
Models of multiple sclerosis: new insights into pathophysiology and repair
Hans Lassmann
CURRENT OPINION IN NEUROLOGY (2008)
Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
G. Calogiuri et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
B cells and multiple sclerosis
Diego Franciotta et al.
LANCET NEUROLOGY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences
Lee S. Schwartzberg et al.
SUPPORTIVE CARE IN CANCER (2008)
Rituximab off label use for difficult-to-treat auto-immune diseases: Reappraisal of benefits and risks
Laurent Sailler
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2008)
Management and preparedness for infusion and hypersensitivity reactions
Heinz-Josef Lenz
ONCOLOGIST (2007)
B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target
Marinos C. Dalakas
PHARMACOLOGY & THERAPEUTICS (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
